Literature DB >> 2914544

Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication).

M J Collen1, V J Stanczak, C A Ciarleglio.   

Abstract

To evaluate possible differences between patients with refractory duodenal ulcers and those with duodenal ulcers that respond to standard doses of antisecretory medications, we determined basal acid outputs by nasogastric suction and daily smoking histories in 75 patients with endoscopically documented active duodenal ulcers. Patients were treated for at least eight weeks with standard doses of antisecretory medications and endoscopic healing or nonhealing was documented. Fifty-five patients that had complete healing of their duodenal ulcers had a mean basal acid output of 6.6 +/- 5.3 meq/hr, and 18/55 had daily cigarette smoking histories, whereas 20 patients that had nonhealing duodenal ulcers had a mean basal acid output of 20.0 +/- 9.6 meq/hr, and 8/20 had daily cigarette smoking histories. There were no significant differences between the two groups with regard to age, duodenal ulcer size, or cigarette smoking history. However, there were significant differences in male-female ratio (P less than 0.02) and in mean basal acid output (P less than 0.001), and all patients with nonhealing duodenal ulcers had basal acid outputs of greater than 10.0 meq/hr. Patients with nonhealing duodenal ulcers were treated with increased doses of ranitidine, mean 675 mg/day (range 600-1200 mg/day), and all had complete healing endoscopically documented. These results indicate that patients treated with standard doses of antisecretory medications with nonhealing duodenal ulcers have increased basal acid outputs of greater than 10.0 meq/hr, and the duodenal ulcers heal with increased doses of antisecretory medication.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2914544     DOI: 10.1007/BF01536057

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome.

Authors:  J P Raufman; S M Collins; S J Pandol; L Y Korman; M J Collen; M J Cornelius; M K Feld; D M McCarthy; J D Gardner; R T Jensen
Journal:  Gastroenterology       Date:  1983-01       Impact factor: 22.682

2.  A comparative trial of ranitidine 300 mg at night with ranitidine 150 mg twice daily in the treatment of duodenal and gastric ulcer.

Authors:  A Farley; D Lévesque; P Paré; A B Thomson; R Sherbaniuk; A Archambault; K Mahoney
Journal:  Am J Gastroenterol       Date:  1985-09       Impact factor: 10.864

3.  Acute treatment of duodenal ulcer: a multicentre study to compare ranitidine 150 mg twice daily with ranitidine 300 mg once at night.

Authors:  F I Lee; P I Reed; J P Crowe; R L McIsaac; J R Wood
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

4.  Reducing overnight secretion of acid to heal duodenal ulcers. Comparison of standard divided dose of ranitidine with a single dose administered at night.

Authors:  D G Colin-Jones; A Ireland; P Gear; P L Golding; J K Ramage; J G Williams; R J Leicester; C L Smith; G Ross; J Bamforth
Journal:  Am J Med       Date:  1984-11-19       Impact factor: 4.965

5.  Treatment of 'cimetidine-resistant' chronic duodenal ulcers with ranitidine or cimetidine: a randomised multicentre study.

Authors:  M Quatrini; G Basilisco; P A Bianchi
Journal:  Gut       Date:  1984-10       Impact factor: 23.059

6.  Cimetidine vs placebo in duodenal ulcer therapy. Six-week controlled double-blind investigation without any antacid therapy.

Authors:  M J Collen; M R Hanan; J A Maher; M Rent; S E Stubrin; J F Arguello; L Gardner
Journal:  Dig Dis Sci       Date:  1980-10       Impact factor: 3.199

7.  Factors influencing healing of duodenal ulcer. Control of nocturnal secretion by H2 blockade and characteristics of patients who failed to heal.

Authors:  S K Lam; C L Lai; L N Lee; K H Fok; M M Ng; K F Siu
Journal:  Dig Dis Sci       Date:  1985-01       Impact factor: 3.199

8.  Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion.

Authors:  M J Collen; J M Howard; K E McArthur; J P Raufman; M J Cornelius; C A Ciarleglio; J D Gardner; R T Jensen
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

9.  Predictors of duodenal ulcer healing and relapse.

Authors:  A Sonnenberg; S A Müller-Lissner; E Vogel; P Schmid; J J Gonvers; P Peter; G Strohmeyer; A L Blum
Journal:  Gastroenterology       Date:  1981-12       Impact factor: 22.682

10.  A multicenter, randomized, double-blind study comparing famotidine with ranitidine in the treatment of active duodenal ulcer disease.

Authors:  A J McCullough
Journal:  Am J Med       Date:  1986-10-24       Impact factor: 4.965

View more
  18 in total

1.  New PC-based program to calculate gastric secretion and emptying using a marker dilution technique.

Authors:  A Dubois; M Mizrahi
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

2.  H2 antagonist and omeprazole nonresponders.

Authors:  V Savarino; G S Mela; S Vigneri; G Celle
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

3.  Definition for idiopathic gastric acid hypersecretion. A statistical and functional evaluation.

Authors:  M J Collen; M J Sheridan
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

4.  Gastric analysis (basal acid output) in nonulcer dyspepsia.

Authors:  M J Collen
Journal:  Dig Dis Sci       Date:  1990-04       Impact factor: 3.199

Review 5.  Formulary management of antiulcer drugs: clinical considerations.

Authors:  S L Sankey; L S Friedman
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

6.  Comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretion.

Authors:  M J Collen; R M Strong
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

7.  Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.

Authors:  K D Bardhan; J Naesdal; G Bianchi Porro; M Petrillo; M Lazzaroni; R F Hinchliffe; M Thompson; P Morris; M J Daly; N J Carroll
Journal:  Gut       Date:  1991-04       Impact factor: 23.059

8.  Markers of slow-healing peptic ulcer in the elderly. A study on 1,052 ranitidine-treated patients.

Authors:  G Battaglia; F Di Mario; P Dotto; G Leandro; A Pilotto; M Ferrana; F Vianello; S Vigneri; C V Colonna; R Naccarato
Journal:  Dig Dis Sci       Date:  1993-08       Impact factor: 3.199

9.  Ranitidine therapy in patients with idiopathic gastric acid hypersecretion. A prospective study.

Authors:  M J Collen; J F Wirshup
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

10.  Bleeding duodenal ulcer. Role of gastric acid hypersecretion.

Authors:  M J Collen; A N Kalloo; M J Sheridan
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.